These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38925899)

  • 1. Treatment Regimens of Neovascular Form of Age-Related Macular Degeneration. A Review.
    Fellner Z; Majtánová N; Kolář P; Krišková P; Kéri P
    Cesk Slov Oftalmol; 2024; 80(Ahead of print):1-7. PubMed ID: 38925899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
    Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ; Couch SM; McCannel CA; Edwards AO
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
    Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
    J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial.
    Ramakrishnan MS; Yu Y; VanderBeek BL
    JAMA Ophthalmol; 2020 Mar; 138(3):237-242. PubMed ID: 32027349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 13. Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice.
    Prieto-Del-Cura M; Villafruela-Güemes I; Recio-Gamo E; Sastre-Ibañez M; Fuentes-Ferrer ME
    J Fr Ophtalmol; 2020 Dec; 43(10):989-995. PubMed ID: 33081995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of neovascular age-related macular degeneration treatment options.
    Holekamp NM
    Am J Manag Care; 2019 Jul; 25(10 Suppl):S172-S181. PubMed ID: 31419088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
    Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
    Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wet age related macular degeneration management and follow-up.
    Alexandru MR; Alexandra NM
    Rom J Ophthalmol; 2016; 60(1):9-13. PubMed ID: 27220225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.
    Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G
    Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks.
    Amarakoon S; Martinez-Ciriano JP; van den Born LI; Baarsma S; Missotten T
    Acta Ophthalmol; 2019 Feb; 97(1):107-112. PubMed ID: 30369062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.